REVIVE THERAPEUTICS LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.03 CAD | 0.00% |
|
+20.00% | 0.00% |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 16.09M 22.15M |
|---|---|---|---|---|---|
| Net income 2022 | -17M -23.4M | Net income 2023 | -6M -8.26M | EV / Sales 2022 | - |
| Net cash position 2022 | 3.59M 4.94M | Net cash position 2023 | 1.87M 2.57M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-8.26
x | P/E ratio 2023 |
-2.42
x | Employees | 2 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 98.54% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 week | +20.00% | ||
| Current month | +20.00% | ||
| 3 months | -14.29% | ||
| 6 months | -14.29% |
1 week
0.03
0.03
1 month
0.030.04
Current year
0.030.04
1 year
0.020.10
3 years
0.020.65
5 years
0.000.92
10 years
0.000.96
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Frank
CEO | Chief Executive Officer | - | 19-12-17 |
Carmelo Marrelli
DFI | Director of Finance/CFO | 52 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michael Frank
CEO | Chief Executive Officer | - | 19-12-17 |
William Jackson
BRD | Director/Board Member | - | 13-12-31 |
Andrew Lindzon
BRD | Director/Board Member | 63 | 19-12-17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.03 | 0.00% | 42 925 |
| 24-04-18 | 0.03 | +20.00% | 30,550 |
| 24-04-17 | 0.025 | 0.00% | 252,000 |
| 24-04-16 | 0.025 | 0.00% | 10,300 |
| 24-04-15 | 0.025 | 0.00% | 1,692 |
Delayed Quote Canadian Securities Exchange, April 18, 2024 at 03:21 pm EDT
More quotes
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Companyâs cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.
Calendar
2024-05-26
- Q3 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 9.13M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.48% | 21.66B | |
| -18.35% | 20.77B | |
| -7.89% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- RVV Stock
